The presentations of Prof Wolinsky at Atrims 2016 are online
Here's the Poster
Actrims 2016 oratorio lb poster wolinsky_lb148 from
BartsMSBlog
There was a difference in atrophy rate between placebo and ocrelizumab, when only you look at gadolinium at baseline verses no gadolinium the results were not difference but the groups were too small to show a difference however people had more MRI than just at baseline and why it was not gadolium positive at any time verses non gadolinium makes me wonder.
So as presented you can not say it only works in people with active disease
CoI ProfG was a Co-author
Labels: ACTRIMS, ocrelizumab